quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·176d
PRRelease
NLS Pharmaceutics Ltd. logo

NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger

NLSP· NLS Pharmaceutics Ltd.
Health Care
Original source

Companies

  • NLSP
    NLS Pharmaceutics Ltd.
    Health Care

Related

  • PR157d
    NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
  • SEC167d
    SEC Form 6-K filed by NLS Pharmaceutics Ltd.
  • SEC169d
    SEC Form POS AM filed by NLS Pharmaceutics Ltd.
  • SEC170d
    Amendment: SEC Form SCHEDULE 13G/A filed by NLS Pharmaceutics Ltd.
  • SEC170d
    SEC Form 6-K filed by NLS Pharmaceutics Ltd.
  • SEC171d
    SEC Form 6-K filed by NLS Pharmaceutics Ltd.
  • SEC175d
    Amendment: SEC Form 25-NSE/A filed by NLS Pharmaceutics Ltd.
  • SEC175d
    SEC Form 6-K filed by NLS Pharmaceutics Ltd.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022